6.80
-0.32(-4.49%)
Currency In USD
| Previous Close | 7.12 |
| Open | 7.12 |
| Day High | 7.13 |
| Day Low | 6.74 |
| 52-Week High | 24.33 |
| 52-Week Low | 3.76 |
| Volume | 16,164 |
| Average Volume | 73,623 |
| Market Cap | 41.84M |
| PE | -0.5 |
| EPS | -13.54 |
| Moving Average 50 Days | 9.14 |
| Moving Average 200 Days | 8.49 |
| Change | -0.32 |
If you invested $1000 in Aligos Therapeutics, Inc. (ALGS) since IPO date, it would be worth $18.32 as of February 21, 2026 at a share price of $6.8. Whereas If you bought $1000 worth of Aligos Therapeutics, Inc. (ALGS) shares 5 years ago, it would be worth $9.32 as of February 21, 2026 at a share price of $6.8.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Aligos Therapeutics Provides Phase 2 B-SUPREME Study Progress Updates
GlobeNewswire Inc.
Jan 21, 2026 1:00 PM GMT
Interim analyses on track for the first and second half of 2026SOUTH SAN FRANCISCO, Calif., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes
Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of James Hassard as Executive Vice President, Chief Commercial Officer
GlobeNewswire Inc.
Jan 13, 2026 1:00 PM GMT
Seasoned leader with global commercialization and marketing expertiseSOUTH SAN FRANCISCO, Calif., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (“Aligos”, Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving
Aligos Therapeutics Presents Positive Data at HEP-DART 2025
GlobeNewswire Inc.
Dec 11, 2025 1:00 PM GMT
Oral presentation of ALG-055009 in vivo nonclinical data showcases synergistic fat mass loss in combination with incretin receptor agonists SOUTH SAN FRANCISCO, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a